Современные представления о роли вирусов как этиологического фактора сепсиса | КМАХ

Современные представления о роли вирусов как этиологического фактора сепсиса

Клиническая микробиология и антимикробная химиотерапия. 2026; 28(1):25-48

​ Григорян Д.А., Горбачева А.А., Мацвай А.Д.
10.36488/cmac.2026.1.25-48
сепсис вирусные инфекции вирусный сепсис этиология септический шок
Раздел
Болезни и возбудители
Тип
Обзор
Публикация
Клиническая микробиология и антимикробная химиотерапия. 2026; 28(1):25-48

Аннотация

Сепсис – жизнеугрожающее состояние, обусловленное дисрегуляцией иммунного ответа на инфекцию, сопровождающееся полиорганной дисфункцией. На протяжении длительного времени роль вирусов в развитии сепсиса оставалась недооцененной ввиду ограниченных возможностей диагностических методов для определения вирусной природы инфекции, а также преобладанием бактериальных возбудителей в структуре заболеваемости. До появления современных молекулярно-генетических методов диагностики случаи сепсиса вирусной природы классифицировались преимущественно как сепсис неуточненной этиологии, искажая реальный вклад вирусных патогенов в общую картину этиологической структуры заболевания. Настоящая работа обобщает сведения о спектре вирусных возбудителей, способных привести к развитию сепсиса, связанных с ним клинических проявлениях, группах риска, а также эпидемиологической ситуации в России и в мире. Представленный обзор современных исследований подчеркивает важность пересмотра традиционных взглядов на этиологию сепсиса и необходимость дальнейшего изучения роли вирусных агентов в развитии этого опасного состояния.

Диана Агароновна Григорян

ФГБУ «Центр стратегического планирования и управления медико-биологическими рисками здоровью» ФМБА России, Москва, Россия

Горбачева А.А.

ФГБУ «Центр стратегического планирования и управления медико-биологическими рисками здоровью» ФМБА России, Москва, Россия

Алина Дмитриевна Мацвай

ФГБУ «Центр стратегического планирования и управления медико-биологическими рисками здоровью» ФМБА России, Москва, Россия

  • 1. Sakr Y., Jaschinski U., Wittebole X., Szakmany T., Lipman J., Ñamendys-Silva S.A., et al. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open Forum Infect Dis. 2018;5(12):ofy313. DOI: 10.1093/ofid/ofy313
  • 2. Dyck B., Unterberg M., Adamzik M., Koos B. The impact of pathogens on sepsis prevalence and outcome. Pathogens. 2024;13(1):89. DOI: 10.3390/pathogens13010089
  • 3. ICD-11 for maintaining mortality and morbidity statistics. Available at: https://icd.who.int/browse/2025-01/mms/ru. Accessed March 02, 2026.
  • 4. Shappell C.N., Klompas M., Chan C., Chen T., Kanjilal S., McKenna C., et al. Use of electronic clinical data to track incidence and mortality for SARS-CoV-2-associated sepsis. JAMA Netw Open. 2023;6(9):e2335728. DOI: 10.1001/jamanetworkopen.2023.35728
  • 5. Karakike E., Giamarellos-Bourboulis E.J., Kyprianou M., Fleischmann-Struzek C., Pletz M.W., Netea M.G., et al. Coronavirus Disease 2019 as cause of viral sepsis: a systematic review and meta-analysis. Crit Care Med. 2021;49(12):2042-2057. DOI: 10.1097/CCM.0000000000005195
  • 6. Southeast Asia Infectious Disease Clinical Research Network. Causes and outcomes of sepsis in southeast Asia: a multinational multicentre cross-sectional study. Lancet Glob Health. 2017;5(2):e157-e167. DOI: 10.1016/S2214-109X(17)30007-4
  • 7. Shi J., Han S., Zhang Y., Lu X., Gan Y., Tong N., et al. Respiratory bacterial and viral pathogen spectrum among influenza-positive and influenza-negative patients. BMC Infect Dis. 2025;25(1):866. DOI: 10.1186/s12879-025-11232-7
  • 8. Xu J.Q., Zhang W.Y., Fu J.J., Fang X.Z., Gao C.G., Li C., et al. Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations. Mil Med Res. 2024;11(1):78. DOI: 10.1186/s40779-024-00581-0
  • 9. Goh C., Burnham K.L., Ansari M.A., de Cesare M., Golubchik T., Hutton P., et al. Epstein-Barr virus reactivation in sepsis due to community-acquired pneumonia is associated with increased morbidity and an immunosuppressed host transcriptomic endotype. Sci Rep. 2020;10(1):9838. DOI: 10.1038/s41598-020-66713-3
  • 10. Srdić T., Đurašević S., Lakić I., Ružičić A., Vujović P., Jevđović T., et al. From molecular mechanisms to clinical therapy: understanding sepsis-induced multiple organ dysfunction. Int J Mol Sci. 2024;25(14):7770. DOI: 10.3390/ijms25147770
  • 11. Yuki K., Koutsogiannaki S. Pattern recognition receptors as therapeutic targets for bacterial, viral and fungal sepsis. Int Immunopharmacol. 2021;98:107909. DOI: 10.1016/j.intimp.2021.107909
  • 12. Gupta N., Richter R., Robert S., Kong M. Viral sepsis in children. Front Pediatr. 2018;6:252. DOI: 10.3389/fped.2018.00252
  • 13. Gürtler L., Schramm W., Seitz R. Viral sepsis – pathophysiology and disease manifestation. Infection. 2025;53(3):775-784. DOI: 10.1007/s15010-025-02486-z
  • 14. Ma L., Li Q., Cai S., Peng H., Huyan T., Yang H. The role of NK cells in fighting the virus infection and sepsis. Int J Med Sci. 2021;18(14):3236-3248. DOI: 10.7150/ijms.59898
  • 15. Joosten S.C.M., Wiersinga W.J., Poll T.V. Dysregulation of host-pathogen interactions in sepsis: host-related factors. Semin Respir Crit Care Med. 2024;45(4):469-478. DOI: 10.1055/s-0044-1787554
  • 16. Zhou K., Chen Y., Pang J., Zhang J., Lu J. The endothelialimmunothrombotic storm in viral sepsis: lessons from COVID-19. Front Immunol. 2025;16:1681764. DOI: 10.3389/fimmu.2025.1681764
  • 17. Simonsen K.A., Anderson-Berry A.L., Delair S.F., Davies H.D. Early-onset neonatal sepsis. Clin Microbiol Rev. 2014;27(1):21-47. DOI: 10.1128/cmr.00031-13
  • 18. Bridwell R.E., Carius B.M., Long B.J., Oliver J.J., Schmitz G. Sepsis in pregnancy: recognition and resuscitation. West J Emerg Med. 2019;20(5):822-832. DOI: 10.5811/westjem.2019.6.43369
  • 19. Huang Y., Li S., Ye W., Wang H., Su J., Gao L., et al. Viral infections in elderly individuals: a comprehensive overview of SARS-CoV-2 and influenza susceptibility, pathogenesis, and clinical treatment strategies. Vaccines. 2025;13(4):431. DOI: 10.3390/vaccines13040431
  • 20. Koçak Tufan Z., Kayaaslan B., Mer M. COVID-19 and Sepsis. Turk J Med Sci. 2021;51(7):3301-3311. DOI: 10.3906/sag-2108-239
  • 21. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. Pediatr Med Rodz. 2020;16(1):9-26. DOI: 10.15557/PiMR.2020.0003
  • 22. Herminghaus A., Osuchowski M.F. How sepsis parallels and differs from COVID-19. eBioMedicine. 2022;86. DOI: 10.1016/j.ebiom.2022.104355
  • 23. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. DOI: 10.1016/S0140-6736(20)30566-3
  • 24. World Health Organization. Severe Acute Respiratory Syndrome (SARS). Available at: www.who.int/healthtopics/severe-acute-respiratory-syndrome. Accessed March 02, 2026.
  • 25. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). Available at: www.who.int/news-room/fact-sheets/detail/middle-eastrespiratory-syndrome-coronavirus-(mers-cov). Accessed March 02, 2026.
  • 26. Centers for Disease Control and Prevention. COVID-19. 2025. People with Certain Medical Conditions and COVID-19 Risk Factors. Available at: www.cdc.gov/covid/risk-factors/index.html. Accessed March 02, 2026.
  • 27. World Health Organization. Clinical characteristics and health outcomes for children hospitalized with COVID-19. Available at: www.who.int/publications/i/item/9789240080119. Accessed March 02, 2026.
  • 28. Booth A., Reed A.B., Ponzo S., Yassaee A., Aral M., Plans D., et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PloS One. 2021;16(3):e0247461. DOI: 10.1371/journal.pone.0247461
  • 29. Treskova-Schwarzbach M., Haas L., Reda S., Pilic A., Borodova A., Karimi K., et al. Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence. BMC Med. 2021;19(1):212. DOI: 10.1186/s12916-021-02058-6
  • 30. van Baar J.A.C., Kostova E.B., Allotey J., Thangaratinam S., Zamora J.R., Bonet M., et al. COVID-19 in pregnant women: a systematic review and meta-analysis on the risk and prevalence of pregnancy loss. Hum Reprod Update. 2024;30(2):133-152. DOI: 10.1093/humupd/dmad030
  • 31. McGowan V.J., Bambra C. COVID-19 mortality and deprivation: pandemic, syndemic, and endemic health inequalities. Lancet Public Health. 2022;7(11):e966-e975. DOI: 10.1016/S2468-2667(22)00223-7
  • 32. Zhang H., Penninger J.M., Li Y., Zhong N., Slutsky A.S. Angiotensin-converting enzyme 2 (ACE2) as a SARSCoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-590. DOI: 10.1007/s00134-020-05985-9
  • 33. Raj V.S., Mou H., Smits S.L., Dekkers D.H.W., Müller M.A., Dijkman R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251-254. DOI: 10.1038/nature12005
  • 34. Stasi A., Castellano G., Ranieri E., Infante B., Stallone G., Gesualdo L., et al. SARS-CoV-2 and viral sepsis: immune dysfunction and implications in kidney failure. J Clin Med. 2020;9(12):4057. DOI: 10.3390/jcm9124057
  • 35. Magro C., Mulvey J.J., Berlin D., Nuovo G., Salvatore S., Harp J., et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res J Lab Clin Med. 2020;220:1-13. DOI: 10.1016/j.trsl.2020.04.007
  • 36. Ali Y.M., Lynch N.J., Khatri P., Bamigbola I.E., Chan A.C.Y., Yabuki M., et al. Secondary complement deficiency impairs anti-microbial immunity to Klebsiella pneumoniae and Staphylococcus aureus during severe acute COVID-19. Front Immunol. 2022;13:841759. DOI: 10.3389/fimmu.2022.841759
  • 37. Kalio A.J., Frank-Peterside N., Cookey T.I., Awanye A.M., Ibezim C.N.E., Onu E.N., et al. SARS-CoV-2 co-infections with bacteria and fungi in symptomatic and asymptomatic COVID-19 patients in Rivers State, Nigeria. Qeios. 2024; DOI: 10.32388/A0WUSC
  • 38. Zhang G., Hu C., Luo L., Fang F., Chen Y., Li J., et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364. DOI: 10.1016/j.jcv.2020.104364
  • 39. Lansbury L., Lim B., Baskaran V., Lim W.S. Co-infections in people with COVID-19: a systematic review and metaanalysis. J Infect. 2020;81(2):266-275. DOI: 10.1016/j.jinf.2020.05.046
  • 40. Bhatt P.J., Shiau S., Brunetti L., Xie Y., Solanki K., Khalid S., et al. Risk factors and outcomes of hospitalized patients with severe Coronavirus Disease 2019 (COVID-19) and secondary bloodstream infections: a multicenter casecontrol study. Clin Infect Dis. 2021;72(12):e995-e1003. DOI: 10.1093/cid/ciaa1748
  • 41. Puzniak L., Finelli L., Yu K.C., Bauer K.A., Moise P., De Anda C., et al. A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19. BMC Infect Dis. 2021;21(1):227. DOI: 10.1186/s12879-021-05877-3
  • 42. Nucci M., Barreiros G., Guimarães L.F., Deriquehem V.A.S., Castiñeiras A.C., Nouér S.A. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. Mycoses. 2021;64(2):152-156. DOI: 10.1111/myc.13225
  • 43. Centers for Disease Control and Prevention. Non-Polio Enterovirus. 2024. Non-Polio Enterovirus Outbreaks. Available at: www.cdc.gov/non-polio-enterovirus/outbreak-surveillance/index.html. Accessed March 02, 2026.
  • 44. Yang X., Duan L., Zhan W., Tang Y., Liang L., Xie J., et al. Enterovirus B types cause severe infection in infants aged 0-3 months. Virol J. 2023;20(1):5. DOI: 10.1186/s12985-023-01965-9
  • 45. Modlin J.F. Perinatal echovirus infection: insights from a literature review of 61 cases of serious infection and 16 outbreaks in nurseries. Rev Infect Dis. 1986;8(6):918-926. DOI: 10.1093/clinids/8.6.918
  • 46. Zhang M., Wang H., Tang J., He Y., Xiong T., Li W., et al. Clinical characteristics of severe neonatal enterovirus infection: a systematic review. BMC Pediatr. 2021;21(1):127. DOI: 10.1186/s12887-021-02599-y
  • 47. Chuang Y.Y., Huang Y.C. Enteroviral infection in neonates. J Microbiol Immunol Infect. 2019;52(6):851-857. DOI: 10.1016/j.jmii.2019.08.018
  • 48. de Jong E.P., van den Beuken M.G.A., van Elzakker E.P.M., Wolthers K.C., Sprij A.J., Lopriore E., et al. Epidemiology of sepsis-like illness in young infants: major role of enterovirus and human parechovirus. Pediatr Infect Dis J. 2018;37(2):113-118. DOI: 10.1097/INF.0000000000001718
  • 49. Ahmad S., Dalwai A., Al-Nakib W. Frequency of enterovirus detection in blood samples of neonates admitted to hospital with sepsis-like illness in Kuwait. J Med Virol. 2013;85(7):1280-1285. DOI: 10.1002/jmv.23604
  • 50. Lv X.Q., Qian L.H., Wu T., Yuan T.M. Enterovirus infection in febrile neonates: a hospital-based prospective cohort study. J Paediatr Child Health. 2016;52(8):837-841. DOI: 10.1111/jpc.13193
  • 51. Piralla A., Mariani B., Stronati M., Marone P., Baldanti F. Human enterovirus and parechovirus infections in newborns with sepsis-like illness and neurological disorders. Early Hum Dev. 2014;90:S75-S77. DOI: 10.1016/S0378-3782(14)70023-4
  • 52. Souverbielle C.T., Feister J., Leber A., Salamon D., Mejias A., Ramilo O., et al. Multiple sites PCR testing for enteroviruses in young febrile infants. Lancet Infect Dis. 2019;19(3):239-240. DOI: 10.1016/S1473-3099(19)30042-8
  • 53. Rhoades R.E., Tabor-Godwin J.M., Tsueng G., Feuer R. Enterovirus infections of the central nervous system. Virology. 2011;411(2):288-305. DOI: 10.1016/j.virol.2010.12.014
  • 54. Huang W.C., Shih W.L., Yang S.C., Yen T.Y., Lee J.T., Huang Y.C., et al. Predicting severe enterovirus 71 infection: age, comorbidity, and parental behavior matter. J Microbiol Immunol Infect. 2017;50(1):10-16. DOI: 10.1016/j.jmii.2014.11.013
  • 55. Gaaloul I., Riabi S., Harrath R., Hunter T., Hamda K.B., Ghzala A.B., et al. Coxsackievirus B detection in cases of myocarditis, myopericarditis, pericarditis and dilated cardiomyopathy in hospitalized patients. Mol Med Rep. 2014;10(6):2811-2818. DOI: 10.3892/mmr.2014.2578
  • 56. Tariq N., Kyriakopoulos C. Group B Coxsackie Virus. В: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available at: www.ncbi.nlm.nih.gov/books/NBK560783. Accessed March 02, 2026.
  • 57. Wang L.C., Tsai H.P., Chen S.H., Wang S.M. Therapeutics for fulminant hepatitis caused by enteroviruses in neonates. Front Pharmacol. 2022;13:1014823. DOI: 10.3389/fphar.2022.1014823
  • 58. Hsia S.H., Lin J.J., Chan O.W., Lin T.Y. Cardiopulmonary failure in children infected with Enterovirus A71. J Biomed Sci. 2020;27(1):53. DOI: 10.1186/s12929-020-00650-1
  • 59. Ong K.C., Wong K.T. Understanding Enterovirus 71 neuropathogenesis and its impact on other neurotropic enteroviruses. Brain Pathol Zurich Switz. 2015;25(5):614-624. DOI: 10.1111/bpa.12279
  • 60. Muehlenbachs A., Bhatnagar J., Zaki S.R. Tissue tropism, pathology and pathogenesis of enterovirus infection. J Pathol. 2015;235(2):217-228. DOI: 10.1002/path.4438
  • 61. Nathan M., Walsh R., Hardin J.T., Einzig S., Connor B.O., Balaguru D., et al. Enteroviral sepsis and ischemic cardiomyopathy in a neonate: case report and review of literature. ASAIO J. 2008;54(5):554. DOI: 10. 1097/MAT.0b013e3181877fc5
  • 62. Wang J.P., Cerny A., Asher D.R., Kurt-Jones E.A., Bronson R.T., Finberg R.W. MDA5 and MAVS mediate type I interferon responses to coxsackie B virus. J Virol. 2010;84(1):254-260. DOI: 10.1128/JVI.00631-09
  • 63. Kuo R.L., Kao L.T., Lin S.J., Wang R.Y.L., Shih S.R. MDA5 plays a crucial role in enterovirus 71 RNA-mediated IRF3 activation. PLoS One. 2013;8(5):e63431. DOI: 10.1371/journal.pone.0063431
  • 64. Wei X., Tu Y., Bu S., Guo G., Wang H., Wang Z. Unraveling the intricate web: complement activation shapes the pathogenesis of sepsis-induced coagulopathy. J Innate Immun. 2024;16(1):337-353. DOI: 10.1159/000539502
  • 65. Barral P.M., Morrison J.M., Drahos J., Gupta P., Sarkar D., Fisher P.B., et al. MDA-5 is cleaved in poliovirus-infected cells. J Virol. 2007;81(8):3677-3684. DOI: 10.1128/jvi.01360-06
  • 66. Lu J., Yi L., Zhao J., Yu J., Chen Y., Lin M.C., et al. Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. J Virol. 2012;86(7):3767-3776. DOI: 10.1128/jvi.06687-11
  • 67. Sandoni M., Ciardo L., Tamburini C., Boncompagni A., Rossi C., Guidotti I., et al. Enteroviral infections in the first three months of life. Pathogens. 2022;11(1):60. DOI: 10.3390/pathogens11010060
  • 68. Lafolie J., Labbé A., L’Honneur A.S., Madhi F., Pereira B., Decobert M., et al. Assessment of blood enterovirus PCR testing in paediatric populations with fever without source, sepsis-like disease, or suspected meningitis: a prospective, multicentre, observational cohort study. Lancet Infect Dis. 2018;18(12):1385-1396. DOI: 10.1016/S1473-3099(18)30479-1
  • 69. Yun K.W., Choi E.H., Cheon D.S., Lee J., Choi C.W., Hwang H., et al. Enteroviral meningitis without pleocytosis in children. Arch Dis Child. 2012;97(10):874-878. DOI: 10.1136/archdischild-2012-301884
  • 70. Itani T., Chalapa V., Semenov A., Sergeev A. Laboratory diagnosis of nonpolio enteroviruses: a review of the current literature. Biosaf Health. 2023;5(2):112-119. DOI: 10.1016/j.bsheal.2022.12.002
  • 71. Kadambari S., Bukasa A., Okike I.O., Pebody R., Brown D., Gallimore C., et al. Enterovirus infections in England and Wales, 2000-2011: the impact of increased molecular diagnostics. Clin Microbiol Infect. 2014;20(12):1289-1296. DOI: 10.1111/1469-0691.12753
  • 72. Jartti M., Flodström-Tullberg M., Hankaniemi M.M. Enteroviruses: epidemic potential, challenges and opportunities with vaccines. J Biomed Sci. 2024;31(1):73. DOI: 10.1186/s12929-024-01058-x
  • 73. Centers for Disease Control and Prevention. Nonpolio enterovirus and human parechovirus surveillance – United States, 2006-2008. MMWR Morb Mortal Wkly Rep. 2010;59(48):1577-1580. PMID: 21150865.
  • 74. Sridhar A., Karelehto E., Brouwer L., Pajkrt D., Wolthers K.C. Parechovirus A pathogenesis and the enigma of genotype A-3. Viruses. 2019;11(11):1062. DOI: 10.3390/v11111062
  • 75. Tao L. Notes from the field: cluster of parechovirus central nervous system infections in young infants – Tennessee, 2022. MMWR Morb Mortal Wkly Rep. 2022;71. DOI: 10.15585/mmwr.mm7130a5
  • 76. Sharp J., Harrison C.J., Puckett K., Selvaraju S.B., Penaranda S., Nix W.A., et al. Characteristics of young infants in whom human parechovirus, enterovirus or neither were detected in cerebrospinal fluid during sepsis evaluations. Pediatr Infect Dis J. 2013;32(3):213. DOI: 10.1097/INF.0b013e318276b328
  • 77. Sasidharan A., Harrison C.J., Banerjee D., Selvarangan R. Emergence of parechovirus A4 central nervous system infections among infants in Kansas City, Missouri, USA. J Clin Microbiol. 2019;57(5):e01698-18. DOI: 10.1128/jcm.01698-18
  • 78. Sasidharan A., Harrison C.J., Selvarangan R. Diagnosis, management, and outcomes of parechovirus infections in infants: an overview. J Clin Microbiol. 2024;62(6):e01139-23. DOI: 10.1128/jcm.01139-23
  • 79. Karelehto E., Cristella C., Yu X., Sridhar A., Hulsdouw R., de Haan K., et al. Polarized entry of human parechoviruses in the airway epithelium. Front Cell Infect Microbiol. 2018;8:294. DOI: 10.3389/fcimb.2018.00294
  • 80. Westerhuis B.M., Koen G., Wildenbeest J.G., Pajkrt D., de Jong M.D., Benschop K.S.M., et al. Specific cell tropism and neutralization of human parechovirus types 1 and 3: implications for pathogenesis and therapy development. J Gen Virol. 2012;93(Pt. 11):2363-2370. DOI: 10.1099/vir.0.043323-0
  • 81. Capendale P.E., García-Rodríguez I., Ambikan A.T., Mulder L.A., Depla J.A., Freeze E., et al. Parechovirus infection in human brain organoids: host innate inflammatory response and not neuro-infectivity correlates to neurologic disease. Nat Commun. 2024;15(1):2532. DOI: 10.1038/s41467-024-46634-9
  • 82. Westerhuis B., Kolehmainen P., Benschop K., Nurminen N., Koen G., Koskiniemi M., et al. Human parechovirus seroprevalence in Finland and the Netherlands. J Clin Virol. 2013;58(1):211-215. DOI: 10.1016/j.jcv.2013.06.036
  • 83. Midgley C.M., Jackson M.A., Selvarangan R., Franklin P., Holzschuh E.L., Lloyd J., et al. Severe parechovirus 3 infections in young infants. J Pediatr Infect Dis Soc. 2018;7(2):104-112. DOI: 10.1093/jpids/pix010
  • 84. Olijve L., Jennings L., Walls T. Human parechovirus: an increasingly recognized cause of sepsis-like illness in young infants. Clin Microbiol Rev. 2017;31(1):e00047-17. DOI: 10.1128/cmr.00047-17
  • 85. Sasidharan A., Banerjee D., Harrison C.J., Selvarangan R. Emergence of parechovirus A3 as the leading cause of central nervous system infection, surpassing any single enterovirus type, in children in Kansas City, Missouri, USA, from 2007 to 2016. J Clin Microbiol. 2021;59(6):e02935-20. DOI: 10.1128/jcm.02935-20
  • 86. Wolthers K.C., Benschop K.S.M., Schinkel J., Molenkamp R., Bergevoet R.M., Spijkerman I.J.B., et al. Human parechoviruses as an important viral cause of sepsis like illness and meningitis in young children. Clin Infect Dis. 2008;47(3):358-363. DOI: 10.1086/589752
  • 87. Skanke L.H., Lysvand H., Heimdal I., Moe N., Krokstad S., Christensen A., et al. Parechovirus A in hospitalized children with respiratory tract infections: a 10-year-long study from Norway. J Pediatr Infect Dis Soc. 2021;10(6):722-729. DOI: 10.1093/jpids/piab009
  • 88. Aizawa Y., Watanabe K., Oishi T., Hirano H., Hasegawa I., Saitoh A. Role of maternal antibodies in infants with severe diseases related to human parechovirus type 3. Emerg Infect Dis. 2015;21(11):1966-1972. DOI: 10.3201/eid2111.150267
  • 89. Izumita R., Aizawa Y., Habuka R., Watanabe K., Otsuka T., Kitamura N., et al. Novel scoring system for differentiating parechovirus-A3 and enterovirus infection in neonates and young infants. J Clin Virol. 2020;124:104256. DOI: 10.1016/j.jcv.2019.104256
  • 90. Centers for Disease Control and Prevention. Recent reports of human parechovirus (PeV) in the United States – 2022. Available at: https://stacks.cdc.gov/view/cdc/119130. Accessed March 02, 2026.
  • 91. Lee B.R., Sasidharan A., Harrison C.J., Selvarangan R. Positive impact of routine testing for enterovirus and parechovirus on length of hospitalization and antimicrobial use among inpatients ≤6 months of age. J Clin Microbiol. 2020;59(1):e02106-20. DOI: 10.1128/jcm.02106-20
  • 92. Centers for Disease Control and Prevention. Enterovirus and human parechovirus surveillance – United States, 2009-2013. Available at: www.cdc.gov/mmwr/preview/mmwrhtml/mm6434a3.htm. Accessed March 02, 2026.
  • 93. Kalil A.C., Thomas P.G. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care Lond Engl. 2019;23(1):258. DOI: 10.1186/s13054-019-2539-x
  • 94. Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012. 2012;87(47):461-476. PMID: 23210147.
  • 95. World Health Organization. Influenza (seasonal). Available at: www.who.int/news-room/fact-sheets/detail/influenza(seasonal). Accessed March 02, 2026.
  • 96. Iuliano A.D., Roguski K.M., Chang H.H., Muscatello D.J., Palekar R., Tempia S., et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285-1300. DOI: 10.1016/S0140-6736(17)33293-2
  • 97. Ortiz J.R., Neuzil K.M., Shay D.K., Rue T.C., Neradilek M.B., Zhou H., et al. The burden of influenzaassociated critical illness hospitalizations. Crit Care Med. 2014;42(11):2325-2332. DOI: 10.1097/CCM.0000000000000545
  • 98. Cillóniz C., Dominedò C., Magdaleno D., Ferrer M., Gabarrús A., Torres A. Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors. J Infect Dis. 2019;220(7):1166-1171. DOI: 10.1093/infdis/jiz257
  • 99. Wong J.Y., Cheung C.M.M., Bond H.S., Cheung J.K., Gao H., Fang V.J., et al. Estimating excess septicaemia mortality and hospitalisation burden associated with influenza in Hong Kong, 1998 to 2019. Epidemiol Infect. 2022;150:e101. DOI: 10.1017/S0950268822000760
  • 100. Dawood F.S., Iuliano A.D., Reed C., Meltzer M.I., Shay D.K., Cheng P.Y., et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-695. DOI: 10.1016/S1473-3099(12)70121-4
  • 101. Marchi S., Manini I., Kistner O., Piu P., Remarque E.J., Manenti A., et al. Serologically-based evaluation of crossprotection antibody responses among different A(H1N1) influenza strains. Vaccines. 2020;8(4):656. DOI: 10.3390/vaccines8040656
  • 102. Centers for Disease Control and Prevention. Serum crossreactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58(19):521-524. PMID: 19478718.
  • 103. Garg S., Jain S., Dawood F.S., Jhung M., Pérez A., D’Mello T., et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection – United States, 2005-2008. BMC Infect Dis. 2015;15:369. DOI: 10.1186/s12879-015-1004-y
  • 104. Casalino E., Antoniol S., Fidouh N., Choquet C., Lucet J.C., Duval X., et al. Influenza virus infections among patients attending emergency department according to main reason to presenting to ED: a 3-year prospective observational study during seasonal epidemic periods. PloS One. 2017;12(8):e0182191. DOI: 10.1371/journal.pone.0182191
  • 105. Li J., Luo Y., Li H., Yin Y., Zhang Y. Research progress of viral sepsis: etiology, pathophysiology, diagnosis, and treatment. Emerg Crit Care Med. 2024;4(2):74. DOI: 10.1097/EC9.0000000000000086
  • 106. Louie J.K., Acosta M., Jamieson D.J., Honein M.A., California Pandemic (H1N1) Working Group. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010;362(1):27-35. DOI: 10.1056/NEJMoa0910444
  • 107. Centers for Disease Control and Prevention. Intensivecare patients with severe novel influenza A (H1N1) virus infection – Michigan, June 2009. MMWR Morb Mortal Wkly Rep. 2009;58(27):749-752. PMID: 19609249.
  • 108. Burrell A., Huckson S., Pilcher D.V., ANZICS. ICU admissions for sepsis or pneumonia in Australia and New Zealand in 2017. N Engl J Med. 2018;378(22):2138-2139. DOI: 10.1056/NEJMc1717178
  • 109. Short K.R., Kroeze E.J.B.V., Fouchier R.A.M., Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014;14(1):57-69. DOI: 10.1016/S1473-3099(13)70286-X
  • 110. Gu X., Zhou F., Wang Y., Fan G., Cao B. Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment. Eur Respir Rev. 2020;29(157):200038. DOI: 10.1183/16000617.0038-2020
  • 111. Florescu D.F., Kalil A.C. The complex link between influenza and severe sepsis. Virulence. 2014;5(1):137-142. DOI: 10.4161/viru.27103
  • 112. Alam A., Jusuf H., Kartasasmita C., Setiabudi D., Sudarwati S., Wulandari D., et al. IL-6 and IFNγ play a role in fatal cases of 5N1 influenza in children. Crit Care. 2012;16(Suppl. 3):P53. DOI: 10.1186/cc11740
  • 113. Brundage J.F., Shanks G.D. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis. 2008;14(8):1193-1199. DOI: 10.3201/eid1408.071313
  • 114. Centers for Disease Control and Prevention. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) – United States, May-August 2009. MMWR Morb Mortal Wkly Rep. 2009;58(38):1071-1074. PMID: 19798021.
  • 115. World Health Organization. Herpes simplex virus. Available at: www.who.int/news-room/fact-sheets/detail/herpessimplex-virus. Accessed March 02, 2026.
  • 116. Brown E.L., Gardella C., Malm G., Prober C.G., ForsgrenM., Krantz E.M., et al. Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. Acta Obstet Gynecol Scand. 2007;86(5):523-529. DOI: 10.1080/00016340601151949
  • 117. Dawood F.S., Iuliano A.D., Reed C., Meltzer M.I., Shay D.K., Cheng P.Y., et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-695. DOI: 10.1016/S1473-3099(12)70121-4
  • 118. Brown Z.A., Wald A., Morrow R.A., Selke S., Zeh J., Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. 2003;289(2):203-209. DOI: 10.1001/jama.289.2.203
  • 119. Haag L.M., Hofmann J., Kredel L.I., Holzem C., Kühl A.A., Taube E.T., et al. Herpes simplex virus sepsis in a young woman with Crohn’s disease. J Crohns Colitis. 2015;9(12):1169-1173. DOI: 10.1093/ecco-jcc/jjv149
  • 120. Kropp R.Y., Wong T., Cormier L., Ringrose A., Burton S., Embree J.E., et al. Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study. Pediatrics. 2006;117(6):1955-1962. DOI: 10.1542/peds.2005-1778
  • 121. Kaufman B., Gandhi S.A., Louie E., Rizzi R., Illei P. Herpes simplex virus hepatitis: case report and review. Clin Infect Dis. 1997;24(3):334-338. DOI: 10.1093/clinids/24.3.334
  • 122. Pinninti S.G., Kimberlin D.W. Neonatal herpes simplex virus infections. Pediatr Clin North Am. 2013;60(2):351-365. DOI: 10.1016/j.pcl.2012.12.005
  • 123. Pinninti S.G., Angara R., Feja K.N., Kimberlin D.W., Leach C.T., Conrad D.A., et al. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J Pediatr. 2012;161(1):134-138.e3. DOI: 10.1016/j.jpeds.2011.12.053
  • 124. Su C., Zhan G., Zheng C. Evasion of host antiviral innate immunity by HSV-1, an update. Virol J. 2016;13:38. DOI: 10.1186/s12985-016-0495-5
  • 125. Miyazaki Y., Akizuki S., Sakaoka H., Yamamoto S., Terao H. Disseminated infection of herpes simplex virus with fulminant hepatitis in a healthy adult. A case report. APMIS. 1991;99(11):1001-1007. DOI: 10.1111/j.1699-0463.1991.tb01292.x
  • 126. Knezevic A., Martic J., Stanojevic M., Jankovic S., Nedeljkovic J., Nikolic L., et al. Disseminated neonatal herpes caused by herpes simplex virus types 1 and 2. Emerg Infect Dis. 2007;13(2):302-304. DOI: 10.3201/eid1302.060907
  • 127. Zuhair M., Smit G.S.A., Wallis G., Jabbar F., Smith C., Devleesschauwer B., et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034. DOI: 10.1002/rmv.2034
  • 128. Aubry A., Francois C., Demey B., Louchet-Ducoroy M., Pannier C., Segard C., et al. Evolution of Epstein-Barr virus infection seroprevalence in a French university hospital over 11 years, including the COVID-19 pandemic, 2013-2023. Microorganisms. 2025;13(4):733. DOI: 10.3390/microorganisms13040733
  • 129. Alyazidi R., Murthy S., Slyker J.A., Gantt S. The potential harm of cytomegalovirus infection in immunocompetent critically ill children. Front Pediatr. 2018;6:96. DOI: 10.3389/fped.2018.00096
  • 130. Zhang Z., Zhang J., Dai S., Fan X., Liu Y., Sun J., et al. Active cytomegalovirus infection in mechanically ventilated patients with sepsis. BMC Infect Dis. 2024;24(1):1405. DOI: 10.1186/s12879-024-10304-4
  • 131. Reactivated HHV-6, CMV, adenovirus and BK virus associated with increased mortality in pediatric sepsis. HHV-6 Foundation. Available at: https://hhv-6foundation.org/transplant-complications/reactivated-hhv-6-cmvadenovirus-and-bk-virus-associated-with-increasedmortality-in-pediatric-sepsis. Accessed March 02, 2026.
  • 132. Cabler S.S., Storch G.A., Weinberg J.B., Walton A.H., Brengel-Pesce K., Aldewereld Z., et al. Viral DNAemia and DNA virus seropositivity and mortality in pediatric sepsis. JAMA Netw Open. 2024;7(2):e240383. DOI: 10.1001/jamanetworkopen.2024.0383
  • 133. Luganini A., Terlizzi M.E., Gribaudo G. Bioactive molecules released from cells infected with the human cytomegalovirus. Front Microbiol. 2016;7:715. DOI: 10.3389/fmicb.2016.00715
  • 134. Souza T.A., Stollar B.D., Sullivan J.L., Luzuriaga K., ThorleyLawson D.A. Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A. 2005;102(50):18093-18098. DOI: 10.1073/pnas.0509311102
  • 135. Jochum S., Moosmann A., Lang S., Hammerschmidt W., Zeidler R. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog. 2012;8(5):e1002704. DOI: 10.1371/journal.ppat.1002704
  • 136. Shi J., Chu C., Yu M., Zhang D., Li Y., Fan Y., et al. Clinical warning of hemophagocytic syndrome caused by EpsteinBarr virus. Ital J Pediatr. 2021;47(1):3. DOI: 10.1186/s13052-020-00949-7
  • 137. Guiouillier F., Derely J., Salvadori A., Pochard J., Le Goff J., Martinez T., et al. Reactivation of Epstein-Barr virus among intensive care patients: a prospective observational study. Intensive Care Med. 2024;50(3):418-426. DOI: 10.1007/s00134-024-07345-3
  • 138. Stéphan F., Thiolière B., Verdy E., Tulliez M. Role of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shock. Clin Infect Dis. 1997;25(5):1159-1164. DOI: 10.1086/516086
  • 139. Mallet F., Perret M., Tran T., Meunier B., Guichard A., Tabone O., et al. Early herpes and TTV DNAemia in septic shock patients: a pilot study. Intensive Care Med Exp. 2019;7(1):28. DOI: 10.1186/s40635-019-0256-z
  • 140. Bichon A., Bourenne J., Allardet-Servent J., Papazian L., Hraiech S., Guervilly C., et al. High mortality of HLH in ICU regardless etiology or treatment. Front Med. 2021;8:735796. DOI: 10.3389/fmed.2021.735796
  • 141. Cui T., Wang J., Wang Z. The outcome of induction therapy for EBV-related hemophagocytic lymphohistiocytosis: a model for risk stratification. Front Immunol. 2022;13:876415. DOI: 10.3389/fimmu.2022.876415
  • 142. Walton A.H., Muenzer J.T., Rasche D., Boomer J.S., Sato B., Brownstein B.H., et al. Reactivation of multiple viruses in patients with sepsis. PloS One. 2014;9(2):e98819. DOI: 10.1371/journal.pone.0098819
  • 143. Jianhua W., Lingjian Z., Yanhao H., Jing L., Enmei L., Na Z. Research progress on human adenovirus sepsis. Front Pediatr. 2025;13:1552958. DOI: 10.3389/fped.2025.1552958
  • 144. Siminovich M., Murtagh P. Acute lower respiratory tract infections by adenovirus in children: histopathologic findings in 18 fatal cases. Pediatr Dev Pathol. 2011;14(3): 214-217. DOI: 10.2350/10-05-0838-OA.1
  • 145. Rajkumar V., Chiang C.S.M., Low J.M., Cui L., Lin R.T.P., Tee N.W.S., et al. Risk factors for severe adenovirus infection in children during an outbreak in Singapore. Ann Acad Med Singapore. 2015;44(2):50-59. PMID: 25797817.
  • 146. Yu Z., Zeng Z., Zhang J., Pan Y., Chen M., Guo Y., et al. Fatal community-acquired pneumonia in children caused by re-emergent human adenovirus 7d associated with higher severity of illness and fatality rate. Sci Rep. 2016;6:37216. DOI: 10.1038/srep37216
  • 147. Tan D., Zhu H., Fu Y., Tong F., Yao D., Walline J., et al. Severe community-acquired pneumonia caused by human adenovirus in immunocompetent adults: a multicenter case series. PloS One. 2016;11(3):e0151199. DOI: 10.1371/journal.pone.0151199
  • 148. Zhang L., Guo Y., Wang X., Gai W., Liu L. Severe adenovirus pneumonia complicated by acute respiratory distress syndrome in immunocompetent patients: a case report and literature review. Front Med. 2025;12:1524783. DOI: 10.3389/fmed.2025.1524783
  • 149. Zhang J., Zhu Y., Zhou Y., Gao F., Qiu X., Li J., et al. Pediatric adenovirus pneumonia: clinical practice and current treatment. Front Med. 2023;10:1207568. DOI: 10.3389/fmed.2023.1207568
  • 150. Hoşnut F.Ö., Ozçay F., Malbora B., Hizli S., Ozbek N. Severe adenovirus infection associated with hemophagocytic lymphohistiocytosis. Turk J Haematol. 2014;31(1):103-105. DOI: 10.4274/Tjh.2013.0218
  • 151. Lahm T., Spartz H.N., Hawley D.A., Leland D.S., Wolf K.M., Twigg H.L., et al. Fatal adenovirus serotype 21 infection associated with hemophagocytic lymphohistiocytosis and multiorgan failure. Respir Med CME. 2010;3(4):223-225. DOI: 10.1016/j.rmedc.2009.11.003
  • 152. Romero-Gómez M.P., Bloise-Sánchez I., Gómez-Arroyo B., González-Donapetry P., Cendejas-Bueno E., GarcíaRodríguez J. Rapid antigen test for adenovirus in children: age and onset of symptoms are important. Enferm Infecc Microbiol Clin (Engl Ed). 2023;41(10):617-620. DOI: 10.1016/j.eimce.2022.09.015
  • 153. Song E., Wang H., Kajon A.E., Salamon D., Dong S., Ramilo O., et al. Diagnosis of pediatric acute adenovirus infections: is a positive PCR sufficient? Pediatr Infect Dis J. 2016;35(8):827-834. DOI: 10.1097/INF.0000000000001119
  • 154. Li Y., Wang X., Blau D.M., Caballero M.T., Feikin D.R., Gill C.J., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047-2064. DOI: 10.1016/S0140-6736(22)00478-0
  • 155. Resch B., Kurath S., Manzoni P. Epidemiology of respiratory syncytial virus infection in preterm infants. Open Microbiol J. 2011:5:135-143. DOI: 10.2174/1874285801105010135
  • 156. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749-1759. DOI: 10.1056/NEJMoa043951
  • 157. Michelin L., Bellei N., Ferreira da Costa Gomes M., Raboni S.M., Kairalla M., Correa R.A., et al. Respiratory syncytial virus: challenges in diagnosis and impact on the elderly: recommendations from a multidisciplinary panel. Hum Vaccines Immunother. 2024;20(1):2388943. DOI: 10.1080/21645515.2024.2388943
  • 158. Havers F.P., Whitaker M., Melgar M., Chatwani B., Chai S.J., Alden N.B., et al. Characteristics and outcomes among adults aged ≥60 years hospitalized with laboratoryconfirmed respiratory syncytial virus – RSV-NET, 12 States, July 2022-June 2023. MMWR Morb Mortal Wkly Rep. 2023;72(40):1075-1082. DOI: 10.15585/mmwr.mm7240a1
  • 159. Alfano F., Bigoni T., Caggiano F.P., Papi A. Respiratory syncytial virus infection in older adults: an update. Drugs Aging. 2024;41(6):487-505. DOI: 10.1007/s40266-024-01118-9
  • 160. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection – a systematic review. Crit Care Lond Engl. 2006;10(4):R107. DOI: 10.1186/cc4984
  • 161. Moore E.C., Barber J., Tripp R.A. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol J. 2008;5:116. DOI: 10.1186/1743-422X-5-116
  • 162. Bakalli I. Liver dysfunction in severe sepsis from respiratory syncytial virus. J Pediatr Intensive Care. 2018;7(2):110-114. DOI: 10.1055/s-0037-1612609
  • 163. Miura H., Hattori F., Uchida H., Hata T., Kudo K., Sato M., et al. Case report of severe myocarditis in an immunocompromised child with Respiratory Syncytial Virus infection. BMC Pediatr. 2018;18(1):51. DOI: 10.1186/s12887-018-1027-9
  • 164. Cebey-López M., Pardo-Seco J., Gómez-Carballa A., Martinón-Torres N., Martinón-Sánchez J.M., JusticiaGrande A., et al. Bacteremia in children hospitalized with respiratory syncytial virus infection. PLoS One. 2016;11(2):e0146599. DOI: 10.1371/journal.pone.0146599
  • 165. Godefroy R., Giraud-Gatineau A., Jimeno M.T., Edouard S., Meddeb L., Zandotti C., et al. Respiratory syncytial virus infection: its propensity for bacterial coinfection and related mortality in elderly adults. Open Forum Infect Dis. 2020;7(12):ofaa546. DOI: 10.1093/ofid/ofaa546
  • 166. Jeannoël M., Lina G., Rasigade J.P., Lina B., Morfin F., Casalegno J.S. Microorganisms associated with respiratory syncytial virus pneumonia in the adult population. Eur J Clin Microbiol Infect Dis. 2019;38(1):157-160. DOI: 10.1007/s10096-018-3407-3
  • 167. Hayek H., Amarin J.Z., Qwaider Y.Z., Khanfar A., Stopczynski T., Schmitz J., et al. Co-detection of respiratory syncytial virus with other respiratory viruses across all age groups before and during the COVID-19 pandemic. Front Virol. 2023;3:1156012. DOI: 10.3389/fviro.2023.1156012
  • 168. Mcmillan J.A., Weiner L.B., Higgins A.M., Macknight K. Rhinovirus infection associated with serious illness among pediatric patients. Pediatr Infect Dis J. 1993;12(4):321-325. DOI: 10.1097/00006454-199304000-00011
  • 169. Liu J., Zhao H., Feng Z., Liu Y., Feng Q., Qian S., et al. A severe case of human rhinovirus A45 with central nervous system involvement and viral sepsis. Virol J. 2022;19(1):72. DOI: 10.1186/s12985-022-01799-x
  • 170. Hung I.F.N., Zhang A.J., To K.K.W., Chan J.F.W., Zhu S.H.S., Zhang R., et al. Unexpectedly higher morbidity and mortality of hospitalized elderly patients associated with rhinovirus compared with influenza virus respiratory tract infection. Int J Mol Sci. 2017;18(2):259. DOI: 10.3390/ijms18020259
  • 171. Drysdale S.B., Mejias A., Ramilo O. Rhinovirus – not just the common cold. J Infect. 2017;74:S41-S16. DOI: 10.1016/S0163-4453(17)30190-1
  • 172. Morelli T., Freeman A., Staples K.J., Wilkinson T.M.A. Hidden in plain sight: the impact of human rhinovirus infection in adults. Respir Res. 2025;26(1):120. DOI: 10.1186/s12931-025-03178-w
  • 173. Boon H., Meinders A.J., van Hannen E.J., Tersmette M., Schaftenaar E. Comparative analysis of mortality in patients admitted with an infection with influenza A/B virus, respiratory syncytial virus, rhinovirus, metapneumovirus or SARS-CoV-2. Influenza Other Respir Viruses. 2024;18(1):e13237. DOI: 10.1111/irv.13237
  • 174. Kennedy J.L., Turner R.B., Braciale T., Heymann P.W., Borish L. Pathogenesis of rhinovirus infection. Curr Opin Virol. 2012;2(3):287-293. DOI: 10.1016/j.coviro.2012.03.008
  • 175. Wang K., Xi W., Yang D., Zheng Y., Zhang Y., Chen Y., et al. Rhinovirus is associated with severe adult community-acquired pneumonia in China. J Thorac Dis. 2017;9(11):4502-4511. DOI: 10.21037/jtd.2017.10.107
  • 176. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-507. DOI: 10.1038/nature12060
  • 177. World Health Organization. Dengue. Available at: www.who.int/news-room/fact-sheets/detail/dengue-andsevere-dengue. Accessed March 02, 2026.
  • 178. Haider N., Hasan M.N., Onyango J., Asaduzzaman M. Global landmark: 2023 marks the worst year for dengue cases with millions infected and thousands of deaths reported. IJID Reg. 2024;13:100459. DOI: 10.1016/j.ijregi.2024.100459
  • 179. Rothman A.L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11(8):532-543. DOI: 10.1038/nri3014
  • 180. Shukla R., Ramasamy V., Shanmugam R.K., Ahuja R., Khanna N. Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine. Front Cell Infect Microbiol. 2020;10. DOI: 10.3389/fcimb.2020.572681
  • 181. Corrales-Aguilar E., Hun-Opfer L. New perspectives on dengue pathogenesis. Acta Médica Costarric. 2012;54(2):75-85.
  • 182. Rajapakse S. Dengue shock. J Emerg Trauma Shock. 2011;4(1):120-127. DOI: 10.4103/0974-2700.76835
  • 183. Yadav A., Kamath A., Gangane N., Choudhary A.A., Prakash A. Unmasking the mimic: when sepsis disguises as dengue shock syndrome. Int J Reprod Contracept Obstet Gynecol. 2024;13(3):765-767. DOI: 10.18203/2320-1770.ijrcog20240497
  • 184. Teparrukkul P., Hantrakun V., Day N.P.J., West T.E., Limmathurotsakul D. Management and outcomes of severe dengue patients presenting with sepsis in a tropical country. PLoS One. 2017;12(4):e0176233. DOI: 10.1371/journal.pone.0176233
  • 185. Alejandria M.M. Dengue haemorrhagic fever or dengue shock syndrome in children. BMJ Clin Evid. 2015;2015:0917. PMID: 25860404.
  • 186. Annan E., Treviño J., Zhao B., Rodriguez-Morales A.J., Haque U. Direct and indirect effects of age on dengue severity: the mediating role of secondary infection. PLoS Negl Trop Dis. 2023;17(8):e0011537. DOI: 10.1371/journal.pntd.0011537
  • 187. Toledo J., George L., Martinez E., Lazaro A., Han W.W., Coelho G.E., et al. Relevance of non-communicable comorbidities for the development of the severe forms of dengue: a systematic literature review. PLoS Negl Trop Dis. 2016;10(1):e0004284. DOI: 10.1371/journal.pntd.0004284
  • 188. Centers for Disease Control and Prevention. Clinical testing guidance for dengue. Available at: www.cdc.gov/dengue/hcp/diagnosis-testing/index.html. Accessed March 02, 2026.
  • 189. Hollingshead C.M., Swinkels H.M., Shah S. Ebola Virus Disease. В: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available at: www.ncbi.nlm.nih.gov/books/NBK560579/. Accessed March 02, 2026.
  • 190. European Centre for Disease Prevention and Control. Factsheet about Ebola disease. Available at: www.ecdc.europa.eu/en/infectious-disease-topics/ebola-virusdisease/facts/factsheet-about-ebola-disease. Accessed March 02, 2026.
  • 191. Wolf T., Kann G., Becker S., Stephan C., Brodt H.R., de Leuw P., et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet. 2015;385(9976):1428-1435. DOI: 10.1016/S0140-6736(14)62384-9
  • 192. World Health Organization. Ebola disease. Available at: www.who.int/news-room/fact-sheets/detail/eboladisease. Accessed March 02, 2026.
  • 193. Centers for Disease Control and Prevention. How Ebola Disease Spreads. Available at: www.cdc.gov/ebola/causes/index.html. Accessed March 02, 2026.
  • 194. Thorson A.E., Deen G.F., Bernstein K.T., Liu W.J., Yamba F., Habib N., et al. Persistence of Ebola virus in semen among Ebola virus disease survivors in Sierra Leone: a cohort study of frequency, duration, and risk factors. PLoS Med. 2021;18(2):e1003273. DOI: 10.1371/journal.pmed.1003273
  • 195. Medina-Rivera M., Centeno-Tablante E., Finkelstein J.L., Rayco-Solon P., Peña-Rosas J.P., Garcia-Casal M.N., et al. Presence of Ebola virus in breast milk and risk of motherto-child transmission: synthesis of evidence. Ann N Y Acad Sci. 2021;1488(1):33-43. DOI: 10.1111/nyas.14519
  • 196. Bower H., Johnson S., Bangura M.S., Kamara A.J., Kamara O., Mansaray S.H., et al. Exposure-specific and age-specific attack rates for Ebola virus disease in Ebola-affected households, Sierra Leone. Emerg Infect Dis. 2016;22(8):1403-1411. DOI: 10.3201/eid2208.160163
  • 197. Li J., Duan H.J., Chen H.Y., Ji Y.J., Zhang X., Rong Y.H., et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis. 2016;42:34-39. DOI: 10.1016/j.ijid.2015.10.021
  • 198. Grinnell M., Dixon M.G., Patton M., Fitter D., Bilivogui P., Johnson C., et al. Ebola virus disease in health care workers – Guinea, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(38):1083-1087. DOI: 10.15585/mmwr.mm6438a6
  • 199. Kilmarx P.H., Clarke K.R., Dietz P.M., Hamel M.J., Husain F., McFadden J.D., et al. Ebola virus disease in health care workers – Sierra Leone, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(49):1168-1171. PMID: 25503921.
  • 200. Ebola virus disease for health professionals. Department for Health and Wellbeing, Adelaide, SA. Available at: www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/clinical+resources/clinical+programs+and+practice+guidelines/infectious+disease+control/ebola+virus+disease/ebola+virus+disease+for+health+professionals. Accessed March 02, 2026.
  • 201. Zhu L., Jin J., Wang T., Hu Y., Liu H., Gao T., et al. Ebola virus sequesters IRF3 in viral inclusion bodies to evade host antiviral immunity. eLife. 2024;12:RP88122. DOI: 10.7554/eLife.88122
  • 202. Bray M., Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis. 2003;188(11):1613-1617. DOI: 10.1086/379727
  • 203. Rojek A., Horby P., Dunning J. Insights from clinical research completed during the west Africa Ebola virus disease epidemic. Lancet Infect Dis. 2017;17(9):e280-e292. DOI: 10.1016/S1473-3099(17)30234-7
  • 204. Uyeki T.M., Mehta A.K., Davey R.T., Liddell A.M., Wolf T., Vetter P., et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016;374(7):636-646. DOI: 10.1056/NEJMoa1504874
  • 205. Sueblinvong V., Johnson D.W., Weinstein G.L., Connor M.J., Crozier I., Liddell A.M., et al. Critical care for multiple organ failure secondary to Ebola virus disease in the United States. Crit Care Med. 2015;43(10):2066-2075. DOI: 10.1097/CCM.0000000000001197
  • 206. World Health Organization. Chikungunya fact sheet. Available at: www.who.int/news-room/fact-sheets/detail/chikungunya. Accessed March 02, 2026.
  • 207. Mavalankar D., Shastri P., Bandyopadhyay T., Parmar J., Ramani K.V. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg Infect Dis. 2008;14(3):412-415. DOI: 10.3201/eid1403.070720
  • 208. de Souza W.M., Ribeiro G.S., de Lima S.T.S., de Jesus R., Moreira F.R.R., Whittaker C., et al. Chikungunya: a decade of burden in the Americas. Lancet Reg Health Am. 2024;30:100673. DOI: 10.1016/j.lana.2023.100673
  • 209. European Centre for Disease Prevention and Control. Chikungunya virus disease case notification rate per 100 000 population, January 2024-December 2024. Available at: www.ecdc.europa.eu/en/publications-data/chikungunya-virus-disease-case-notification-rate-100-000-population-january-2024. Accessed March 02, 2026.
  • 210. Hsu C.H., Cruz-Lopez F., Vargas Torres D., PerezPadilla J., Lorenzi O.D., Rivera A., et al. Risk factors for hospitalization of patients with chikungunya virus infection at sentinel hospitals in Puerto Rico. PLoS Negl Trop Dis. 2019;13(1):e0007084. DOI: 10.1371/journal.pntd.0007084
  • 211. Pedí V.D., Porto D.L., de Jesus Martins W., de França G.V.A. Epidemiology of Chikungunya hospitalizations, Brazil, 2014-2024. Emerg Infect Dis. 2025;31(9):1718-1728. DOI: 10.3201/eid3109.250554
  • 212. Rollé A., Schepers K., Cassadou S., Curlier E., Madeux B., Hermann-Storck C., et al. Severe sepsis and septic shock associated with chikungunya virus infection, Guadeloupe, 2014. Emerg Infect Dis. 2016;22(5):891-894. DOI: 10.3201/eid2205.151449
  • 213. Göertz G.P., McNally K.L., Robertson S.J., Best S.M., Pijlman G.P., Fros J.J. The Methyltransferase-like domain of chikungunya virus nsP2 inhibits the interferon response by promoting the nuclear export of STAT1. J Virol. 2018;92(17):e01008-18. DOI: 10.1128/JVI.01008-18
  • 214. Koeltz A., Lastere S., Jean-Baptiste S. Intensive care admissions for severe chikungunya virus infection, French Polynesia. Emerg Infect Dis. 2018;24(4):794-796. DOI: 10.3201/eid2404.161536
  • 215. Crosby L., Perreau C., Madeux B., Cossic J., Armand C., Herrmann-Storke C., et al. Severe manifestations of chikungunya virus in critically ill patients during the 2013-2014 Caribbean outbreak. Int J Infect Dis. 2016;48:78-80. DOI: 10.1016/j.ijid.2016.05.010
  • 216. European Centre for Disease Prevention and Control. Disease information about hantavirus. 2017. Available at: www.ecdc.europa.eu/en/hantavirus-infection/facts. Accessed March 02, 2026.
  • 217. Martínez V.P., Di Paola N., Alonso D.O., Pérez-Sautu U., Bellomo C.M., Iglesias A.A., et al. «Super-spreaders» and person-to-person transmission of Andes virus in Argentina. N Engl J Med. 2020;383(23):2230-2241. DOI: 10.1056/NEJMoa2009040
  • 218. Toledo J., Haby M.M., Reveiz L., Sosa Leon L., Angerami R., Aldighieri S. Evidence for Human-to-human transmission of hantavirus: a systematic review. J Infect Dis. 2022;226(8):1362-1371. DOI: 10.1093/infdis/jiab461
  • 219. Moore R.A., Griffen D. Hantavirus pulmonary syndrome. В: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available at: http://ncbi.nlm.nih.gov/books/NBK513243/. Accessed March 02, 2026.
  • 220. Lu W., Kuang L., Hu Y., Shi J., Li Q., Tian W. Epidemiological and clinical characteristics of death from hemorrhagic fever with renal syndrome: a meta-analysis. Front Microbiol. 2024;15:1329683. DOI: 10.3389/fmicb.2024.1329683
  • 221. Bi Z., Formenty P.B.H., Roth C.E. Hantavirus infection: a review and global update. J Infect Dev Ctries. 2008;2(1):3-23. DOI: 10.3855/jidc.317
  • 222. Park Y. Epidemiologic study on changes in occurrence of hemorrhagic fever with renal syndrome in Republic of Korea for 17years according to age group: 2001-2017. BMC Infect Dis. 2019;19(1):153. DOI: 10.1186/s12879-019-3794-9
  • 223. Vial P.A., Ferrés M., Vial C., Klingström J., Ahlm C., López R., et al. Hantavirus in humans: a review of clinical aspects and management. Lancet Infect Dis. 2023;23(9):e371-e382. DOI: 10.1016/S1473-3099(23)00128-7
  • 224. Manigold T., Vial P. Human hantavirus infections: epidemiology, clinical features, pathogenesis and immunology. Swiss Med Wkly. 2014;144(1112): w13937-w13937. DOI: 10.4414/smw.2014.13937
  • 225. Mackow E.R., Gavrilovskaya I.N. Hantavirus regulation of endothelial cell functions. Thromb Haemost. 2009;102(6):1030-1041. DOI: 10.1160/TH09-09-0640
  • 226. Zou L.X., Chen M.J., Sun L. Haemorrhagic fever with renal syndrome: literature review and distribution analysis in China. Int J Infect Dis. 2016;43:95-100. DOI: 10.1016/j.ijid.2016.01.003
  • 227. Jiang H., Du H., Wang L.M., Wang P.Z., Bai X.F. Hemorrhagic fever with renal syndrome: pathogenesis and clinical picture. Front Cell Infect Microbiol. 2016;6:1. DOI: 10.3389/fcimb.2016.00001
  • 228. Janwadkar R.S., Ritchie H.M., Johnson C.A. Unexpected challenges: a case report of hantavirus infection in a pregnant patient in a rural emergency department. J Emerg Med. 2025;77:84-88. DOI: 10. 1016/j.jemermed.2025.07.045
  • 229. Bugedo G., Florez J., Ferres M., Roessler E., Bruhn A. Hantavirus cardiopulmonary syndrome successfully treated with high-volume hemofiltration. Rev Bras Ter Intensiva. 2016;28(2):190-194. DOI: 10.5935/0103-507X.20160032
  • 230. Hennig J., Rosson J., Curry K. A complex case of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome. Crit Care Med. 2024;52(1):S249. DOI: 10.1097/01.ccm.0001000380.16526.9a
  • 231. Krautkrämer E., Zeier M., Plyusnin A. Hantavirus infection: an emerging infectious disease causing acute renal failure. Kidney Int. 2013;83(1):23-27. DOI: 10.1038/ki.2012.360
  • 232. Chen X., Wang H., Li Q., Qi Y., Li F., He W., et al. A fatal case of neonatal viral sepsis caused by human parainfluenza virus type 3. Virol J. 2023;20(1):248. DOI: 10.1186/s12985-023-02141-9
  • 233. Al Bishawi A., Ben Abid F., Ibrahim W. Bocavirus infection in a young pregnant woman: a case report and literature review. Am J Case Rep. 2021;22:e928099. DOI: 10.12659/AJCR.928099
  • 234. Tomatis Souverbielle C., Sánchez P.J., Erdem G. Metapneumovirus infections are uncommon in infants younger than 60 days of age admitted for sepsis evaluation. Pediatr Infect Dis J. 2023;42(2):e52. DOI: 10.1097/INF.0000000000003769
  • 235. Ogunkunle T.O., Bello S.O., Anderson C.I., Musa R., Olaosebikan R., Imam A. Fatal case of newborn Lassa fever virus infection mimicking late onset neonatal sepsis: a case report from northern Nigeria. Infect Dis Poverty. 2020;9(1):110. DOI: 10.1186/s40249-020-00731-1
  • 236. Lei X.Y., Liu M.M., Yu X.J. Severe fever with thrombocytopenia syndrome and its pathogen SFTSV. Microbes Infect. 2015;17(2):149-154. DOI: 10.1016/j.micinf.2014.12.002
  • 237. Kim E.H., Park S.J. Emerging tick-borne Dabie bandavirus: virology, epidemiology, and prevention. Microorganisms. 2023;11(9):2309. DOI: 10.3390/microorganisms11092309
  • 238. Silva Jr. J.M., dos Santos S.D.S. Sepsis in AIDS patients: clinical, etiological and inflammatory characteristics. J Int AIDS Soc. 2013;16(1):17344. DOI: 10.7448/IAS.16.1.17344
  • 239. Noursadeghi M., Katz D.R., Miller R.F. HIV-1 infection of mononuclear phagocytic cells: the case for bacterial innate immune deficiency in AIDS. Lancet Infect Dis. 2006;6(12):794-804. DOI: 10.1016/S1473-3099(06)70656-9
  • 240. Collini P., Noursadeghi M., Sabroe I., Miller R.F., Dockrell D.H. Monocyte and macrophage dysfunction as a cause of HIV-1 induced dysfunction of innate immunity. Curr Mol Med. 2010;10(8):727-740. DOI: 10.2174/156652410793384141
  • 241. Gea-Banacloche J.C., Opal S.M., Jorgensen J., Carcillo J.A., Sepkowitz K.A., Cordonnier C. Sepsis associated with immunosuppressive medications: an evidencebased review. Crit Care. 2004;32(Suppl. 11):S578-S590. DOI: 10.1097/01.ccm.0000143020.27340.ff
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились